REGENXBIO (NASDAQ:RGNX) Shares Down 3.7%

REGENXBIO Inc. (NASDAQ:RGNX) fell 3.7% during mid-day trading on Thursday . The stock traded as low as $12.20 and last traded at $12.24. 58,263 shares traded hands during trading, a decline of 90% from the average session volume of 600,573 shares. The stock had previously closed at $12.71.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Barclays lowered their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th. The Goldman Sachs Group assumed coverage on REGENXBIO in a research report on Friday, June 7th. They issued a “buy” rating and a $38.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of REGENXBIO in a report on Wednesday, September 4th. Finally, StockNews.com downgraded shares of REGENXBIO from a “hold” rating to a “sell” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.91.

REGENXBIO Stock Up 5.4 %

The firm has a 50-day moving average price of $12.38 and a 200 day moving average price of $15.37. The firm has a market capitalization of $634.55 million, a PE ratio of -2.18 and a beta of 1.22.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.24. The business had revenue of $22.30 million during the quarter, compared to analyst estimates of $22.97 million. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.66) earnings per share. Equities research analysts expect that REGENXBIO Inc. will post -4.66 earnings per share for the current year.

Insider Buying and Selling at REGENXBIO

In related news, CEO Curran Simpson sold 9,648 shares of REGENXBIO stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $15.04, for a total transaction of $145,105.92. Following the completion of the sale, the chief executive officer now owns 170,137 shares in the company, valued at approximately $2,558,860.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Curran Simpson sold 9,648 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $15.04, for a total transaction of $145,105.92. Following the completion of the sale, the chief executive officer now directly owns 170,137 shares in the company, valued at approximately $2,558,860.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $11.27, for a total value of $112,700.00. Following the completion of the transaction, the director now directly owns 11,286 shares in the company, valued at $127,193.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,279 shares of company stock valued at $875,634. 13.13% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RGNX. Charles Schwab Investment Management Inc. boosted its position in REGENXBIO by 0.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 327,451 shares of the biotechnology company’s stock valued at $5,878,000 after buying an additional 1,683 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in REGENXBIO by 174.4% in the fourth quarter. BNP Paribas Financial Markets now owns 67,760 shares of the biotechnology company’s stock valued at $1,216,000 after purchasing an additional 43,070 shares during the last quarter. Jump Financial LLC acquired a new stake in REGENXBIO during the 4th quarter valued at approximately $644,000. Dimensional Fund Advisors LP increased its holdings in REGENXBIO by 2.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,226,957 shares of the biotechnology company’s stock worth $22,025,000 after purchasing an additional 34,385 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its position in shares of REGENXBIO by 2.4% in the 4th quarter. Panagora Asset Management Inc. now owns 222,363 shares of the biotechnology company’s stock valued at $3,991,000 after purchasing an additional 5,184 shares in the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.